Bayer To Battle For Antitumor Market In China
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare has received China State FDA's approval for Nexavar (sorafenib), its oral drug for treating patients with advanced hepatocellular carcinoma that cannot be removed by surgery. Nexavar, first launched in 2005 in the U.S., represents Bayer's first oncology heavyweight. Industry insiders observe that the drug's speedy launch in China reflects the company's ambition in the antitumor field. According to WHO officials, antitumor drugs in recent years have become the fastest growing sector in China. Several pharmaceutical MNCs are launching their latest antitumor offerings to corner the market. Meanwhile, Simcere Pharmaceutical's acquisition of China-developed cancer drug Endostar (recombinant human endostatin) has opened the door for local firms to contend for a share of the pie. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.